NCT02224534

Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction

High PlatElet Inhibition With TicAgrelor to Improve Left Ventricular RemodeLING in Patients With ST-segment ElevAtion Myocardial Infarction: the HEALING-AMI Trial.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 326 (estimated)
• Sponsor: Gyeongsang National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the novel role of ticagrelor to improve long-term LV remodeling following ST-segment elevation myocardial infarction.

Detailed description

The investigators designed the HEALING-AMI study to compare the influence of ticagrelor (180 mg loading and 90 mg twice daily maintenance) vs. clopidogrel (600 mg loading and 75 mg daily maintenance) on long-term left ventricular (LV) remodeling measured by 3D echocardiography in STEMI patients undergoing primary PCI. The primary objective of the HEALING-AMI study is to demonstrate the novel role of long-term ticagrelor therapy in reducing the risk of LV remodeling,. The secondary objectives are to reveal the cross-talk between platelet and inflammatory process in ST-segment elevation myocardial infarction (STEMI) patients. Moreover, this study will determine whether the high platelet inhibition by ticagrelor culminate the protection of infarcted myocardium.

Conditions

• ST Elevation Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Ticagrelor	Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
DRUG	Clopidogrel	Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.

Timeline

• Start date: 2014-10-01
• Primary completion: 2017-06-01
• Completion: 2017-12-01
• First posted: 2014-08-25
• Last updated: 2016-11-15

Locations

12 sites across 3 countries: China, Singapore, South Korea